Practice guidelines for the diagnosis and management of microcytic anemias due to genetic disorders of iron metabolism or heme synthesis

Blood

Volumn 123, Issue 25, 2014, Pages 3873-3886

  Donker, Albertine E ^a   Raymakers, Reinier A P ^b   Thom Vlasveld, L ^c   Van Barneveld, Teus ^d   Terink, Rieneke ^a   Dors, Natasja ^e   Brons, Paul P T ^a   Knoers, Nine V A M ^b   Swinkels, Dorine W ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c MEDICAL CENTER HAAGLANDEN   (Netherlands)

^d Dutch Association of Medical Specialists   (Netherlands)

^e CATHARINA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABCB7 PROTEIN; ALAS2 PROTEIN; APOTRANSFERRIN; CP PROTEIN; FECH PROTEIN; FERRITIN; FERROPORTIN 1; FRESH FROZEN PLASMA; HEME; HEPCIDIN; IRON; PROTEIN; PROTOPORPHYRIN; PYRIDOXINE; SLC11A2 PROTEIN; SLC25A38 PROTEIN; TMPRSS6 PROTEIN; TRANSCRIPTION FACTOR GATA 1; UNCLASSIFIED DRUG; UROPORPHYRINOGEN III SYNTHASE; ZINC SULFATE;

ACERULOPLASMINEMIA; ANEMIA WITH SYSTEMIC IRON LOADING; ATAXIA; AUTOSOMAL RECESSIVE INHERITANCE; CEREBELLAR ATAXIA; CONGENITAL ERYTHROPOIETIC PORPHYRIA; DISEASE FREE SURVIVAL; ERYTHROCYTE TRANSFUSION; ERYTHROID PRECURSOR CELL; ERYTHROPOIESIS; ERYTHROPOIETIC PROTOPORPHYRIA; FERRITIN BLOOD LEVEL; FERROPORTIN DISEASE; GAIN OF FUNCTION MUTATION; GENE MUTATION; GENETIC DISORDER; GENOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEME SYNTHESIS; HEMOCHROMATOSIS; HUMAN; IRON CHELATION; IRON DEFICIENCY ANEMIA; IRON METABOLISM; IRON METABOLISM DISORDER; IRON OVERLOAD; MICROCYTIC ANEMIA; PATHOGENESIS; PATHOGENICITY; PEDIATRICIAN; PHLEBOTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RARE DISEASE; REVIEW; SIDEROBLASTIC ANEMIA; TRANSFERRIN DEFICIENCY; X LINKED SIDEROBLASTIC ANEMIA;

ANEMIA, HYPOCHROMIC; ANEMIA, IRON-DEFICIENCY; ANEMIA, SIDEROBLASTIC; EVIDENCE-BASED MEDICINE; GENETIC PREDISPOSITION TO DISEASE; HEME; HUMANS; IRON; MUTATION; PRACTICE GUIDELINES AS TOPIC;

EID: 84902664348     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-01-548776     Document Type: Review

References (101)

1. Iolascon A, De Falco L, Beaumont C. Molecular basis of inherited microcytic anemia due to defects in iron acquisition or heme synthesis. Haematologica. 2009;94(3):395-408.
2. van Rooijen KL, Raymakers RA, Cuijpers ML, Brons PP, Janssen MC, Swinkels DW. New causes of microcytic anaemia: hereditary disorders of iron homeostasis [in Dutch]. Ned Tijdschr Geneeskd. 2010;154:A1039.
3. Camaschella C. Recent advances in the understanding of inherited sideroblastic anaemia. Br J Haematol. 2008;143(1):27-38.
4. Fleming MD. Congenital sideroblastic anemias: iron and heme lost in mitochondrial translation. Hematology (Am Soc Hematol Educ Program). 2011;2011:525-531.
5. Camaschella C. Hereditary sideroblastic anemias: pathophysiology, diagnosis, and treatment. Semin Hematol. 2009;46(4):371-377.
6. Donovan A, Brownlie A, Zhou Y, et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature. 2000;403(6771):776-781. (Pubitemid 30111839)
7. Kautz L, Jung G, Nemeth E, Ganz T. The erythroid factor erythroferrone and its role in iron homeostasis [abstract]. Blood. 2013;122(21). Abstract 4.
8. Borry P, Goffin T, Nys H, Dierickx K. Attitudes regarding predictive genetic testing in minors: a survey of European clinical geneticists. Am J Med Genet C Semin Med Genet. 2008;148C(1):78-83. (Pubitemid 351294855)
9. Godard B, Hurlimann T, Letendre M, Egalité N; INHERIT BRCAs. Guidelines for disclosing genetic information to family members: from development to use. Fam Cancer. 2006;5(1):103-116. (Pubitemid 43384325)
10. Mol BW, van Triest B, Arends AJ, et al. Kwaliteitskoepel medische dpecialisten. http://www.kwaliteitskoepel.nl/assets/structured-files/2012/ Richtlijn+2-Opmaak+5.pdf. Accessed January 9, 2014.
11. Brouwers MC, Kho ME, Browman GP, et al; AGREE Next Steps Consortium. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ. 2010;182(18):E839-E842.
12. Atkins D, Best D, Briss PA, et al; GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490.
13. Guyatt GH, Oxman AD, Vist GE, et al; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-926. (Pubitemid 351632017)
14. Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of Mammalian iron metabolism. Cell. 2010;142(1):24-38.
15. Grantham-McGregor S, Ani C. A review of studies on the effect of iron deficiency on cognitive development in children. J Nutr. 2001;131(2S-2):649S- 666S.
16. Fleming RE, Ponka P. Iron overload in human disease. N Engl J Med. 2012;366(4):348-359.
17. Du X, She E, Gelbart T, et al. The serine protease TMPRSS6 is required to sense iron deficiency. Science. 2008;320(5879):1088-1092. (Pubitemid 351929552)
18. Silvestri L, Guillem F, Pagani A, et al. Molecular mechanisms of the defective hepcidin inhibition in TMPRSS6 mutations associated with iron-refractory iron deficiency anemia. Blood. 2009;113(22):5605-5608.
19. Finberg KE, Heeney MM, Campagna DR, et al. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet. 2008;40(5):569-571. (Pubitemid 351601217)
20. Benyamin B, Ferreira MA, Willemsen G, et al. Common variants in TMPRSS6 are associated with iron status and erythrocyte volume. Nat Genet. 2009;41(11):1173-1175.
21. Chambers JC, Zhang W, Li Y, et al. Genome-wide association study identifies variants in TMPRSS6 associated with hemoglobin levels. Nat Genet. 2009;41(11):1170-1172.
22. Melis MA, Cau M, Congiu R, et al. A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron. Haematologica. 2008;93(10):1473-1479.
23. Hershko C, Camaschella C. How I treat unexplained refractory iron deficiency anemia. Blood. 2014;123(3):326-333.
24. Heeney MM, Campagna DR, Westerman M, Fleming MD. The clinical and genetic spectrum of TMPRSS6 mutations leading to inappropriate hepcidin expression and iron refractory iron deficiency anemia (IRIDA) [abstract]. Blood. 2009;114(22). Abstract 629.
25. Beutler E, Van Geet C, te Loo DM, et al. Polymorphisms and mutations of human TMPRSS6 in iron deficiency anemia. Blood Cells Mol Dis. 2010;44(1):16-21.
26. Cau M, Galanello R, Giagu N, Melis MA. Responsiveness to oral iron and ascorbic acid in a patient with IRIDA. Blood Cells Mol Dis. 2012;48(2):121-123.
27. Locatelli F, Bárány P, Covic A, et al; ERA-EDTA ERBP Advisory Board. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant. 2013;28(6):1346-1359.
28. Lehmberg K, Grosse R, Muckenthaler MU, et al. Administration of recombinant erythropoietin alone does not improve the phenotype in iron refractory iron deficiency anemia patients. Ann Hematol. 2013;92(3):387-394.
29. Ramsay AJ, Quesada V, Sanchez M, et al. Matriptase-2 mutations in iron-refractory iron deficiency anemia patients provide new insights into protease activation mechanisms. Hum Mol Genet. 2009;18(19):3673-3683.
30. Kroot JJ, Tjalsma H, Fleming RE, Swinkels DW. Hepcidin in human iron disorders: diagnostic implications. Clin Chem. 2011;57(12):1650-1669.
31. Wallace DF, Harris JM, Subramaniam VN. Functional analysis and theoretical modeling of ferroportin reveals clustering of mutations according to phenotype. Am J Physiol Cell Physiol. 2010;298(1):C75-C84.
32. De Domenico I, Ward DM, Langelier C, et al. The molecular mechanism of hepcidin-mediated ferroportin down-regulation. Mol Biol Cell. 2007;18(7):2569-2578. (Pubitemid 47025722)
33. Pietrangelo A. The ferroportin disease. Blood Cells Mol Dis. 2004;32(1):131-138. (Pubitemid 38147710)
34. Camaschella C, Poggiali E. Rare types of genetic hemochromatosis. Acta Haematol. 2009;122(2-3):140-145.
35. Mayr R, Janecke AR, Schranz M, et al. Ferroportin disease: a systematic meta-analysis of clinical and molecular findings. J Hepatol. 2010;53(5):941-949.
36. Nemeth E. Ferroportin mutations: a tale of two phenotypes. Blood. 2005;105(10):3763-3764. (Pubitemid 40656113)
37. Rice AE, Mendez MJ, Hokanson CA, Rees DC, Björkman PJ. Investigation of the biophysical and cell biological properties of ferroportin, a multipass integral membrane protein iron exporter. J Mol Biol. 2009;386(3):717-732.
38. Blanc B, Finch CA, Hallberg L, et al. Nutritional anemias. Report of a WHO Scientific Group. WHO Tech Rep Ser. 1968;405:1-40.
39. Harris ZL, Durley AP, Man TK, Gitlin JD. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. Proc Natl Acad Sci USA. 1999;96(19):10812-10817. (Pubitemid 29442226)
40. De Domenico I, Ward DM, di Patti MC, et al. Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI-ceruloplasmin. EMBO J. 2007;26(12):2823-2831. (Pubitemid 46975784)
41. Miyajima H, Kohno S, Takahashi Y, Yonekawa O, Kanno T. Estimation of the gene frequency of aceruloplasminemia in Japan. Neurology. 1999;53(3):617-619. (Pubitemid 29382060)
42. McNeill A, Pandolfo M, Kuhn J, Shang H, Miyajima H. The neurological presentation of ceruloplasmin gene mutations. Eur Neurol. 2008;60(4):200-205.
43. Bosio S, De Gobbi M, Roetto A, et al. Anemia and iron overload due to compound heterozygosity for novel ceruloplasmin mutations. Blood. 2002;100(6):2246-2248. (Pubitemid 35001263)
44. Roberti Mdo R, Borges Filho HM, Gonçalves CH, Lima FL. Aceruloplasminemia: a rare disease - diagnosis and treatment of two cases. Rev Bras Hematol Hemoter. 2011;33(5):389-392.
45. Suzuki Y, Yoshida K, Aburakawa Y, et al. Effectiveness of oral iron chelator treatment with deferasirox in an aceruloplasminemia patient with a novel ceruloplasmin gene mutation. Intern Med. 2013;52(13):1527-1530.
46. Finkenstedt A, Wolf E, Höfner E, et al. Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation. J Hepatol. 2010;53(6):1101-1107.
47. Kuhn J, Bewermeyer H, Miyajima H, Takahashi Y, Kuhn KF, Hoogenraad TU. Treatment of symptomatic heterozygous aceruloplasminemia with oral zinc sulphate. Brain Dev. 2007;29(7):450-453. (Pubitemid 46755537)
48. Skidmore FM, Drago V, Foster P, Schmalfuss IM, Heilman KM, Streiff RR. Aceruloplasminaemia with progressive atrophy without brain iron overload: treatment with oral chelation. J Neurol Neurosurg Psychiatry. 2008;79(4):467-470. (Pubitemid 351441511)
49. Logan JI, Harveyson KB, Wisdom GB, Hughes AE, Archbold GP. Hereditary caeruloplasmin deficiency, dementia and diabetes mellitus. QJM. 1994;87(11):663-670.
50. Yazaki M, Yoshida K, Nakamura A, et al. A novel splicing mutation in the ceruloplasmin gene responsible for hereditary ceruloplasmin deficiency with hemosiderosis. J Neurol Sci. 1998;156(1):30-34. (Pubitemid 28141035)
51. Beutler E, Gelbart T, Lee P, Trevino R, Fernandez MA, Fairbanks VF. Molecular characterization of a case of atransferrinemia. Blood. 2000;96(13):4071-4074.
52. Heilmeyer L, Keller W, Vivell O, et al. Congenital atransferrinemia in a 7-year-old girl [in German]. Dtsch Med Wochenschr. 1961;86:1745-1751.
53. Hayashi A, Wada Y, Suzuki T, Shimizu A. Studies on familial hypotransferrinemia: unique clinical course and molecular pathology. Am J Hum Genet. 1993;53(1):201-213. (Pubitemid 23313751)
54. Trombini P, Coliva T, Nemeth E, et al. Effects of plasma transfusion on hepcidin production in human congenital hypotransferrinemia. Haematologica. 2007;92(10):1407-1410. (Pubitemid 350144159)
55. Bartnikas TB, Andrews NC, Fleming MD. Transferrin is a major determinant of hepcidin expression in hypotransferrinemic mice. Blood. 2011;117(2):630-637.
56. Shamsian BS, Rezaei N, Arzanian MT, Alavi S, Khojasteh O, Eghbali A. Severe hypochromic microcytic anemia in a patient with congenital atransferrinemia. Pediatr Hematol Oncol. 2009;26(5):356-362.
57. Hamill RL, Woods JC, Cook BA. Congenital atransferrinemia. A case report and review of the literature. Am J Clin Pathol. 1991;96(2):215-218.
58. Hromec A, Payer J Jr, Killinger Z, Rybár I, Rovenský J. Congenital atransferrinemia [in German]. Dtsch Med Wochenschr. 1994;119(18):663-666.
59. Goldwurm S, Casati C, Venturi N, et al. Biochemical and genetic defects underlying human congenital hypotransferrinemia. Hematol J. 2000;1(6):390-398.
60. Canonne-Hergaux F, Zhang AS, Ponka P, Gros P. Characterization of the iron transporter DMT1 (NRAMP2/DCT1) in red blood cells of normal and anemic mk/mk mice. Blood. 2001;98(13):3823-3830.
61. Fleming MD, Trenor CC III, Su MA, et al. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat Genet. 1997;16(4):383-386. (Pubitemid 27323306)
62. Touret N, Martin-Orozco N, Paroutis P, et al. Molecular and cellular mechanisms underlying iron transport deficiency in microcytic anemia. Blood. 2004;104(5):1526-1533. (Pubitemid 39166534)
63. Priwitzerova M, Pospisilova D, Prchal JT, et al. Severe hypochromic microcytic anemia caused by a congenital defect of the iron transport pathway in erythroid cells. Blood. 2004;103(10):3991-3992. (Pubitemid 38596326)
64. Iolascon A, Camaschella C, Pospisilova D, Piscopo C, Tchernia G, Beaumont C. Natural history of recessive inheritance of DMT1 mutations. J Pediatr. 2008;152(1):136-139. (Pubitemid 350265942)
65. Iolascon A, d'Apolito M, Servedio V, Cimmino F, Piga A, Camaschella C. Microcytic anemia and hepatic iron overload in a child with compound heterozygous mutations in DMT1 (SCL11A2). Blood. 2006;107(1):349-354.
66. Ohgami RS, Campagna DR, Greer EL, et al. Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells. Nat Genet. 2005;37(11):1264-1269. (Pubitemid 41568711)
67. Ohgami RS, Campagna DR, Antiochos B, et al. nm1054: a spontaneous, recessive, hypochromic, microcytic anemia mutation in the mouse. Blood. 2005;106(10):3625-3631. (Pubitemid 41609203)
68. Grandchamp B, Hetet G, Kannengiesser C, et al. A novel type of congenital hypochromic anemia associated with a nonsense mutation in the STEAP3/TSAP6 gene. Blood. 2011;118(25):6660-6666.
69. Guernsey DL, Jiang H, Campagna DR, et al. Mutations in mitochondrial carrier family gene SLC25A38 cause nonsyndromic autosomal recessive congenital sideroblastic anemia. Nat Genet. 2009;41(6):651-653.
70. Kannengiesser C, Sanchez M, Sweeney M, et al. Missense SLC25A38 variations play an important role in autosomal recessive inherited sideroblastic anemia. Haematologica. 2011;96(6):808-813.
71. Taketani S, Kakimoto K, Ueta H, Masaki R, Furukawa T. Involvement of ABC7 in the biosynthesis of heme in erythroid cells: interaction of ABC7 with ferrochelatase. Blood. 2003;101(8):3274-3280. (Pubitemid 36858024)
72. Allikmets R, Raskind WH, Hutchinson A, Schueck ND, Dean M, Koeller DM. Mutation of a putative mitochondrial iron transporter gene (ABC7) in X-linked sideroblastic anemia and ataxia (XLSA/A). Hum Mol Genet. 1999;8(5):743-749. (Pubitemid 29189041)
73. Bottomley SS, Healy HM, Brandenburg MA, May BK. 5-Aminolevulinate synthase in sideroblastic anemias: mRNA and enzyme activity levels in bone marrow cells. Am J Hematol. 1992;41(2):76-83.
74. Astner I, Schulze JO, van den Heuvel J, Jahn D, Schubert WD, Heinz DW. Crystal structure of 5-aminolevulinate synthase, the first enzyme of heme biosynthesis, and its link to XLSA in humans. EMBO J. 2005;24(18):3166-3177. (Pubitemid 41348692)
75. Campagna DR, de Bie CI, Schmitz-Abe K, et al. X-linked sideroblastic anemia due to ALAS2 intron 1 enhancer element GATA-binding site mutations. Am J Hematol. 2014;89(3):315-319.
76. Cotter PD, May A, Li L, et al. Four new mutations in the erythroid-specific 5-aminolevulinate synthase (ALAS2) gene causing X-linked sideroblastic anemia: increased pyridoxine responsiveness after removal of iron overload by phlebotomy and coinheritance of hereditary hemochromatosis. Blood. 1999;93(5):1757-1769. (Pubitemid 29102505)
77. Cooley TB. A severe type of hereditary anemia with elliptocytosis. Interesting sequence of splenectomy. Am J Med Sci. 1945;209:561-568.
78. Bergmann AK, Campagna DR, McLoughlin EM, et al. Systematic molecular genetic analysis of congenital sideroblastic anemia: evidence for genetic heterogeneity and identification of novel mutations. Pediatr Blood Cancer. 2010;54(2):273-278.
79. Ducamp S, Kannengiesser C, Touati M, et al. Sideroblastic anemia: molecular analysis of the ALAS2 gene in a series of 29 probands and functional studies of 10 missense mutations. Hum Mutat. 2011;32(6):590-597.
80. Aivado M, Gattermann N, Rong A, et al. X-linked sideroblastic anemia associated with a novel ALAS2 mutation and unfortunate skewed X-chromosome inactivation patterns. Blood Cells Mol Dis. 2006;37(1):40-45. (Pubitemid 44062359)
81. Cazzola M, May A, Bergamaschi G, Cerani P, Rosti V, Bishop DF. Familial-skewed X-chromosome inactivation as a predisposing factor for late-onset X-linked sideroblastic anemia in carrier females. Blood. 2000;96(13):4363-4365.
82. Harris JW, Danish EH, Brittenham GM, McLaren CE. Pyridoxine responsive hereditary sideroblastic erythropoiesis and iron overload: two microcytic subpopulations in the affected male, one normocytic and one microcytic subpopulation in the obligate female carrier. Am J Hematol. 1993;42(4):400-401. (Pubitemid 23104816)
83. Barton JC, Lee PL. Disparate phenotypic expression of ALAS2 R452H (nt 1407 G - > A) in two brothers, one with severe sideroblastic anemia and iron overload, hepatic cirrhosis, and hepatocellular carcinoma. Blood Cells Mol Dis. 2006;36(3):342-346. (Pubitemid 43776183)
84. Furuyama K, Harigae H, Kinoshita C, et al. Late-onset X-linked sideroblastic anemia following hemodialysis. Blood. 2003;101(11):4623-4624. (Pubitemid 36857837)
85. Cotter PD, Rucknagel DL, Bishop DF. X-linked sideroblastic anemia: identification of the mutation in the erythroid-specific delta-aminolevulinate synthase gene (ALAS2) in the original family described by Cooley. Blood. 1994;84(11):3915-3924. (Pubitemid 24362493)
86. Camaschella C. Treating iron overload. N Engl J Med. 2013;368(24):2325- 2327.
87. Ye H, Jeong SY, Ghosh MC, et al. Glutaredoxin 5 deficiency causes sideroblastic anemia by specifically impairing heme biosynthesis and depleting cytosolic iron in human erythroblasts. J Clin Invest. 2010;120(5):1749-1761.
88. Ye H, Rouault TA. Erythropoiesis and iron sulfur cluster biogenesis. Adv Hematol. 2010;2010:329394.
89. Camaschella C, Campanella A, De Falco L, et al. The human counterpart of zebrafish shiraz shows sideroblastic-like microcytic anemia and iron overload. Blood. 2007;110(4):1353-1358. (Pubitemid 47281436)
90. Balwani M, Doheny D, Bishop DF, et al; Porphyrias Consortium of the National Institutes of Health Rare Diseases Clinical Research Network. Loss-of-function ferrochelatase and gain-of-function erythroid-specific 5-aminolevulinate synthase mutations causing erythropoietic protoporphyria and x-linked protoporphyria in North American patients reveal novel mutations and a high prevalence of X-linked protoporphyria. Mol Med. 2013;19:26-35.
91. Whatley SD, Mason NG, Holme SA, Anstey AV, Elder GH, Badminton MN. Molecular epidemiology of erythropoietic protoporphyria in the U.K. Br J Dermatol. 2010;162(3):642-646.
92. Holme SA, Worwood M, Anstey AV, Elder GH, Badminton MN. Erythropoiesis and iron metabolism in dominant erythropoietic protoporphyria. Blood. 2007;110(12):4108-4110. (Pubitemid 350248469)
93. Delaby C, Lyoumi S, Ducamp S, et al. Excessive erythrocyte PPIX influences the hematologic status and iron metabolism in patients with dominant erythropoietic protoporphyria. Cell Mol Biol (Noisy-le-grand). 2009;55(1):45-52.
94. Balwani M, Desnick RJ. The porphyrias: advances in diagnosis and treatment. Hematology (Am Soc Hematol Educ Program). 2012;2012:19-27.
95. Fritsch C, Bolsen K, Ruzicka T, Goerz G. Congenital erythropoietic porphyria. J Am Acad Dermatol. 1997;36(4):594-610. (Pubitemid 27164493)
96. Solis C, Aizencang GI, Astrin KH, Bishop DF, Desnick RJ. Uroporphyrinogen III synthase erythroid promoter mutations in adjacent GATA1 and CP2 elements cause congenital erythropoietic porphyria. J Clin Invest. 2001;107(6):753-762. (Pubitemid 32225361)
97. Phillips JD, Steensma DP, Pulsipher MA, Spangrude GJ, Kushner JP. Congenital erythropoietic porphyria due to a mutation in GATA1: the first trans-acting mutation causative for a human porphyria. Blood. 2007;109(6):2618-2621. (Pubitemid 46425911)
98. Katugampola RP, Badminton MN, Finlay AY, et al. Congenital erythropoietic porphyria: a single-observer clinical study of 29 cases. Br J Dermatol. 2012;167(4):901-913.
99. Martinez Peinado C, Díaz de Heredia C, To-Figueras J, et al. Successful treatment of congenital erythropoietic porphyria using matched unrelated hematopoietic stem cell transplantation. Pediatr Dermatol. 2013;30(4):484-489.
100. Piomelli S, Poh-Fitzpatrick MB, Seaman C, Skolnick LM, Berdon WE. Complete suppression of the symptoms of congenital erythropoietic porphyria by long-term treatment with high-level transfusions. N Engl J Med. 1986;314(16):1029-1031. (Pubitemid 16138698)
101. Desnick RJ, Astrin KH. Congenital erythropoietic porphyria: advances in pathogenesis and treatment. Br J Haematol. 2002;117(4):779-795. (Pubitemid 34639239)